Na+/K+-ATPase and cancer.

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• The sodium pump (Na(+)/K(+)-ATPase) is implicated in cancer development and progression.
• Abnormal expression and activity of Na(+)/K(+)-ATPase are observed in various cancers.
• Na(+)/K(+)-ATPase subunits show differential expression in malignant versus normal tissues, suggesting diagnostic potential.

Purpose of the Study:

• To review significant patents focusing on Na(+)/K(+)-ATPase as an anticancer target.
• To highlight novel Na(+)/K(+)-ATPase inhibitors and ligands for cancer therapy.

Main Methods:

• Literature review of scientific publications.
• Analysis of patent applications related to Na(+)/K(+)-ATPase inhibitors.
• Overview of Na(+)/K(+)-ATPase's role in cancer signaling and adhesion.

Main Results:

• Na(+)/K(+)-ATPase is a versatile signal transducer and key in cell adhesion.
• Patent applications increasingly claim Na(+)/K(+)-ATPase inhibitors for cancer treatment.
• Cardiac glycosides and other novel compounds are explored as anticancer agents targeting Na(+)/K(+)-ATPase.

Conclusions:

• Na(+)/K(+)-ATPase represents a valuable therapeutic target for anticancer drug development.
• Emerging inhibitors show potential for treating cancers resistant to conventional therapies.
• Further research into Na(+)/K(+)-ATPase inhibitors could lead to new cancer treatment strategies.